Sabine D. Brookman-May, Professor of Urology at Munich University and Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“Excellent summary on NMIBC and UTUC treatment, diagnostics and biomarkers from EAU26 by Joost Boormans.
Key takeaways on NMIBC and utDNA/urine biomarkers:
- Erdafitinib-iDRS shows strong activity as ablative treatment in FGFR-altered IR-NMIBC → 6-month CR rate: 89% + as adjuvant treatment in BCG-treated HR-NMIBC, adjuvant erdafitinib shows → 1-year RFS: 83%
- utDNA highly prognostic → patients #MRD-negative at baseline and week 12 had ~100% 1-yr RFS #THOR2
- For HR-NMIBC, strategies that may shape future care are optimized intravesical therapy (e.g. BCG + MMC) + biomarker-guided surveillance
- Opens promising perspectives for biomarker-guided follow-up and treatment decisions
Diagnostics in UTUC are evolving and we see some practice-relevant signals.
PET-CT improves staging of high-risk UTUC
→ ~18% of patients were upstaged vs CT
→ ~17% treatment escalation
Urine DNA methylation markers may help replace diagnostic ureteroscopy in selected cases
→ AUC ≈ 0.97 ”
Other articles featuring Sabine D. Brookman-May on OncoDaily.
